CLSI Sensitivity Breakpoints for Klebsiella pneumoniae
For current clinical practice, you must consult the most recent CLSI M100 document (33rd edition, 2023) for up-to-date susceptibility breakpoints for Klebsiella pneumoniae, as breakpoints have undergone multiple revisions over the past decade and continue to evolve based on pharmacokinetic/pharmacodynamic data and clinical outcomes 1.
Key Historical Context and Current Considerations
The CLSI has significantly revised interpretive criteria for Enterobacteriaceae (now Enterobacterales) multiple times since 2010, particularly affecting how we interpret susceptibility for K. pneumoniae 2.
Major Breakpoint Changes You Need to Know
Cephalosporins:
- Ceftazidime susceptible breakpoint: Revised to ≤4 μg/mL (2010 update) 2
- Cefepime susceptible breakpoint: Remained at ≤8 μg/mL 2
- These revised breakpoints eliminated the routine need for ESBL confirmatory testing before reporting results, though ESBL detection remains valuable for infection control and epidemiological purposes 2
Critical Clinical Caveat: The 2010 cephalosporin breakpoints failed to identify many ESBL-producing K. pneumoniae isolates. Studies show that 44.6% of ESBL-producers were susceptible to ceftazidime and 55.4% to cefepime using these criteria 3. This creates a significant clinical risk, as ESBL production is associated with poor outcomes in bacteremia from non-urinary sources 4.
Carbapenems:
- New interpretive breakpoints were established to detect carbapenemase-producing organisms without requiring Modified Hodge Test (MHT) screening 2
- Ertapenem: The revised breakpoints resulted in 12% of previously susceptible ESBL-producing K. pneumoniae becoming non-susceptible (susceptibility dropped from 90% to 78%) 2
- The intermediate category for carbapenems was introduced to capture isolates with MICs in ranges associated with carbapenemase production 2
Piperacillin-Tazobactam:
- Most recently revised in 2022: susceptible ≤8/4 μg/mL, susceptible dose-dependent 16/4 μg/mL, resistant ≥32/4 μg/mL 5
Practical Laboratory Implementation Issues
Automated System Limitations
If your laboratory uses automated systems (Vitek II or Phoenix), be aware that MIC ranges for certain agents (cefazolin, ertapenem in both systems; ceftriaxone in Phoenix) cannot detect susceptible or intermediate isolates using newer breakpoints 2. This requires manual testing or alternative methods for accurate categorization.
ESBL Testing Recommendations
Despite CLSI stating routine ESBL testing is no longer necessary with revised breakpoints, you should continue ESBL screening and confirmatory testing for K. pneumoniae because:
- Many ESBL-producers remain susceptible to cephalosporins by current criteria but have worse clinical outcomes 3, 4
- ESBL detection is essential for infection control measures 2
- Regional areas with high ESBL burden (like Taiwan, parts of Europe) particularly benefit from continued testing 2
Carbapenemase Detection
Rapid molecular testing for specific carbapenemase types (KPC, NDM, VIM, OXA-48-like) is strongly recommended because treatment strategies differ significantly based on carbapenemase class 6. Time to appropriate therapy directly impacts mortality in critically ill patients with carbapenemase-producing K. pneumoniae bacteremia 6.
Geographic and Resistance Pattern Considerations
- KPC remains most common globally (47.4% of carbapenem-resistant isolates), followed by MBLs (20.6%) and OXA-48-like (19.0%) 6
- Europe: ST11-KL64 with KPC-2 is the dominant hypervirulent carbapenem-resistant clone; ST101, ST147, and ST512 are emerging, with ST147 associated with OXA-48 and NDM 7
- Hypervirulent strains (hvKP) are increasingly acquiring carbapenem resistance, creating particularly dangerous hv-CRKP strains 7, 8
Clinical Implications for Antibiotic Selection
When treating K. pneumoniae infections, do not rely solely on automated susceptibility reports. Consider:
For KPC-producing strains: Ceftazidime-avibactam and meropenem-vaborbactam are first-line; imipenem-relebactam and cefiderocol are alternatives 6
For MBL-producers: Aztreonam remains active (unlike other β-lactams) and should be combined with other agents; classic β-lactamase inhibitors do not work against MBLs 6
For ESBL-producers with cephalosporin-susceptible MICs: Exercise caution, especially for non-urinary infections, as clinical failure rates are significantly higher despite in vitro susceptibility 4